DS-9231 in Intermediate-risk (Sub-massive) Acute Pulmonary Embolism (PE)
Status:
Withdrawn
Trial end date:
2020-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate safety and initial effectiveness of
DS-9231 when taken together with current standard of care. Evaluation will be done with low,
medium and then high doses of DS-9231 versus placebo, in participants with medium-risk acute
pulmonary embolism.